London
United Kingdom
King’s College London - Department of Twin Research and Genetic Epidemiology
COVID-19; vaccination; Phase IV trial; Pfizer-BioNTech; Oxford/AstraZeneca; BNT162b2; ChAdOx1 nCoV-19